Scapulatempo-Neto Cristovam, Veo Carlos, Fregnani José Humberto T G, Lorenzi Adriana, Mafra Allini, Melani Armando G F, Loaiza Edgar Antonio Alemán, Rosa Luciana Albina Reis, de Oliveira Cristina Mendes, Levi José Eduardo, Longatto-Filho Adhemar
Department of Pathology (CSN), Barretos Cancer Hospital, Pio XII Foundation, Barretos, São Paulo, SP 14784-400, Brazil.
Department of Surgery, Barretos Cancer Hospital, Pio XII Foundation, Barretos, São Paulo, SP 14784-400, Brazil.
Oncol Lett. 2017 Mar;13(3):1891-1898. doi: 10.3892/ol.2017.5650. Epub 2017 Jan 25.
The present study aimed to ascertain the significance of topoisomerase II α (TOP2A) and minichromosome maintenance protein (MCM) 2 expression in anal carcinoma. A total of 75 anal lesions were retrieved from the files of the Department of Pathology of Barretos Cancer Hospital (Barretos, Brazil) in order to verify the human papillomavirus (HPV) statuses of these lesions and characterize the immunohistochemical expression levels of TOP2A and MCM2 in anal carcinoma, as these are important markers for cervical HPV-induced lesions; their expression was also compared with respect to p16 and Ki-67. The vast majority of the cases tested positive for HPV16 (84%); 1 case tested positive for both HPV16 and HPV18. Positive HPV16 status was more frequent in early stages than in advanced stages (P=0.008). Positive immunohistochemical reactivity for MCM2 and TOP2A protein was observed in 71.6 and 100% of cases, respectively. Positive reactivity for p16 was significantly associated (P=0.001) with histological grade, and was more commonly expressed in squamous cell carcinoma than adenocarcinomas. HPV16 was strongly associated with positive p16 protein expression (76.6%). However, the high expression of Ki-67 combined with the high expression of p16 was predominantly observed in Stage III-IV cases. MCM2, TOP2A, p16 and Ki-67 exhibited intense positive staining in the anal lesions, indicating that these markers were significantly and constantly expressed in anal carcinoma.
本研究旨在确定拓扑异构酶IIα(TOP2A)和微小染色体维持蛋白(MCM)2在肛管癌中的表达意义。从巴西巴雷图癌症医院病理科档案中检索了75例肛门病变样本,以核实这些病变的人乳头瘤病毒(HPV)状态,并确定TOP2A和MCM2在肛管癌中的免疫组化表达水平,因为它们是宫颈HPV诱导病变的重要标志物;还将它们的表达与p16和Ki-67进行了比较。绝大多数检测病例HPV16呈阳性(84%);1例HPV16和HPV18均呈阳性。HPV16阳性在早期比晚期更常见(P=0.008)。分别在71.6%和100%的病例中观察到MCM2和TOP2A蛋白的免疫组化阳性反应。p16阳性反应与组织学分级显著相关(P=0.001),在鳞状细胞癌中比腺癌中更常表达。HPV16与p16蛋白阳性表达密切相关(76.6%)。然而,Ki-67高表达与p16高表达主要见于III-IV期病例。MCM2、TOP2A、p16和Ki-67在肛门病变中均呈强阳性染色,表明这些标志物在肛管癌中显著且持续表达。